Follows pregnant women taking ozanimod and their babies' health
Observes outcomes in pregnant women with multiple sclerosis who take ozanimod.
Key facts
- Who runs it
- Bristol-Myers Squibb
- Where
- Bethesda, United StatesSee the 2 sitesAlso in 1 other country, 1 site
- Trial code
- Registry title
- A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
- Status
- Recruiting
- People taking part
- 1,182 people, planned
- Started
- 15 Jul 2022
- Expected to end
- 30 Jun 2032
- Type of study
- Observational, 3 groups
- Record updated
- 20 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with multiple sclerosis (MS) who are pregnant now or were pregnant recently. It follows how ozanimod exposure affects mother and baby.
- Sex
- Women only.
- Disease stage
- Diagnosis of multiple sclerosis (MS).
- Earlier treatment
- People who took other S1P therapies, cladribine, or mitoxantrone during the first trimester cannot join.
Main reasons for not taking part
- Exposure to other S1P therapies during the first trimester
- Exposure to cladribine during the first trimester
- Exposure to mitoxantrone during the first trimester
- Not living in the United States, Canada or Germany
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Diagnosis of Multiple sclerosis (MS)
- Currently or recently pregnant
- Reside in the United States, Canada or Germany
Who cannot take part
- Exposure to other S1P therapies, cladribine, or mitoxantrone during the first trimester; Other protocol-defined inclusion/exclusion criteria apply
Where in United States
Also in 1 other country, 1 site
- EvideraBethesda, United StatesContact: Marielle Bassel, Site 0001Taking people
- Evidera INC.Bethesda, United StatesContact: Marielle Bassel, Site 0003Taking people
About the trial
What the trial wants to find out
The purpose of this study is to provide information on maternal, fetal, and infant outcomes following exposure of ozanimod during pregnancy so that participants and physicians can weigh the benefits and risks of exposure to the pharmaceutical during pregnancy and make informed treatment decisions.
The 3 groups in the trial
- Ozanimod-exposed participants
Women with a diagnosis of multiple sclerosis (MS) who are exposed to ozanimod during the exposure window.
- Comparator-exposed participants
Women with a diagnosis of MS who are not exposed to ozanimod or other sphingosine 1-phosphate (S1P) therapies during the exposure window but who are exposed to other products approved to treat MS during the exposure window.
- Unexposed participants
Women with a diagnosis of MS who are not exposed to ozanimod or other products approved to treat MS during the exposure window.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- ZEPOSIA® (Ozanimod) Pregnancy Registry: A Prospective, Observational Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
- Plain-language title
- Follows pregnant women taking ozanimod and their babies' healthGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 20 November 2025